NRG-GU014
Open to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
Principal Investigator
Co-Principal Investigator(s)
Status
Open to Accrual
Date Opened To Accrual
March 7, 2025
Disease Site
Genitourinary [GU] Bladder
Phase
II
Developmental Therapeutics
Yes
Primary Objective
To compare bladder-intact event-free survival.
Patient Population
Pathologically (histologically) proven diagnosis of T1 high-grade non-muscle invasive urothelial carcinoma of the bladder
without radiographic evidence of regional nodal disease or metastatic disease.
Target Accrual
160
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
To learn more about this study, visit the Patient Study Webpage.
-
Share this study.
-
-
-
-
